| Autor: |
Yaseen M Taher, Ali M Almothaffar, Bassam Francis Matti, Alaa Fadhil Alwan |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Iraqi Journal of Hematology, Vol 7, Iss 2, Pp 67-71 (2018) |
| Druh dokumentu: |
article |
| ISSN: |
2072-8069 |
| DOI: |
10.4103/ijh.ijh_2_18 |
| Popis: |
Background: Nilotinib is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) and in patients with CML-CP and accelerated phase (CML-AP) who are resistant to or intolerant of imatinib. Patients with imatinib-resistant CML, nilotinib treatment resulted in a significant proportion of patients achieving hematologic and cytogenetic responses in all phases of CML. Objectives: The aim of the present study was to assess the treatment outcomes in term of the molecular response rate of CML patients using Nilotinib as the second-line therapy after failure of imatinib therapy. Patients and Methods: A prospective study conducted between December 2014 and December 2016 in Baghdad Teaching Hospital and National Centre of hematology. A total of 100 patients, who were on nilotinib therapy as the second-line therapy, were enrolled in this study. The molecular response was assessed using real-time quantitative polymerase chain reaction (RQ-PCR). Major molecular response (MMR) was defined as the BCR-ABL1 of |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
